兰诺拉用于改善非阻塞性冠状动脉疾病患者的冠状动脉微血管功能:随机对照试验的试验顺序分析的系统审查和元分析
Hao Ling1, Sunjing Fu2,3, Mengting Xu2,3
1Department of Radiology, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, China.
Quantitative imaging in medicine and surgery
|February 28, 2024
概括
兰诺素可以改善冠状动脉微血管功能,在患有非阻塞性冠状动脉疾病的患者. 这种抗血管性药物增强了冠状动脉流量储备,心肌 perfusion 和生活质量,对于关键结果具有足够的统计能力.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 翻译医学是一种翻译医学.
背景情况:
- 微血管功能障碍是非阻塞性冠状动脉疾病的一个重要问题.
- 兰诺是一种抗血管性药物,对微血管功能有潜在的益处.
- 这项研究系统地审查了Ranolazine在该患者群体中的有效性.
研究的目的:
- 评估兰诺拉在改善冠状动脉微血管功能的疗效.
- 评估罗纳拉对冠状动脉流量储备和心肌 perfusion 的影响.
- 分析Ranolazine对胸痛症状和生活质量的影响.
主要方法:
- 随机对照试验 (RCT) 的系统审查和元分析.
- 搜索了多个数据库 (科克兰图书馆,PubMed,Embase等) 在2023年9月之前.
- 包括8个RCT与379名参与者;评估偏差风险和执行子组分析.
主要成果:
- 兰诺在8-12周内显著增加了冠状动脉流量储备 (CFR) (SMD=1.16,P=0.002).
- 观察到的全球心肌输液储备指数 (MPRI) (WMD=0.18,P=0.002) 和中下心脏MPRI (WMD=0.10,P=0.02) 的改善.
- 兰诺素改善了身体功能,心痛稳定性和生活质量得分 (SAQ).
结论:
- 兰洛在非阻塞性冠状动脉疾病中增强冠状动脉微血管功能方面表现出有效性.
- 在心肌输液和患者报告的结果 (SAQ分数) 中发现了改善.
- 建议进行较大的长期RCT以进一步验证和全面理解.
更多相关视频
07:53Standardized Rat Coronary Ring Preparation and Real-Time Recording of Dynamic Tension Changes Along Vessel Diameter
Published on: June 16, 2022
3.2K
08:35Oxygenation-sensitive Cardiac MRI with Vasoactive Breathing Maneuvers for the Non-invasive Assessment of Coronary Microvascular Dysfunction
Published on: August 17, 2022
2.4K
相关概念视频
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
512
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
512
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
429
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
429
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
01:23Antihypertensive Drugs: Vasodilators
519
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
519
01:16Antianginal Drugs: Nitrates and β-Blockers
586
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
586
01:22Heart Failure Drugs: β-Blockers
338
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
338